December 12, 2007 - According to research published in the December issue of the Journal of Nuclear Medicine, PET/CT imaging exhibits significantly higher sensitivity, specificity and accuracy than conventional imaging when it comes to detecting malignant tumors in children, and provides doctors with additional information about cancer in children, possibly sparing young patients from being overtreated.

The study found that PET/CT can detect small lymph node lesions diagnosed as negative with conventional (or anatomical) imaging and deny the presence of active disease in soft-tissue masses post-treatment, especially in children with a wide range of malignant cancers.

Researchers reviewed 151 FDG PET/CT exams that were performed on 55 children with noncentral nervous system malignancies (30 patients had lymphoma, cancer that affects the body's lymph nodes and other organs that are part of the body's immune and blood-forming systems).

According to the study, PET with CT imaging, with the radiotracer fluorodeoxyglucose (FDG) enables the collection of both biological and anatomical information during a single exam, with PET picking up metabolic signals of body cells and tissues and CT offering a detailed map of internal anatomy. When there were discrepancies between PET/CT and conventional anatomical imaging in analyzing cancer lesions, PET/CT was diagnostically accurate 90 percent of the time. Doctors monitor the radiation dose given to children in imaging exams, generally using lower doses than that of adult patients, to get adequate exam results,

The study says PET is a powerful molecular imaging procedure that noninvasively demonstrates the function of organs and other tissues. When PET is used to image cancer, a radiopharmaceutical (such as FDG, which includes both a sugar and a radionuclide) is injected into a patient. Cancer cells metabolize sugar at higher rates than normal cells, and the radiopharmaceutical is drawn in higher amounts to cancerous areas. PET scans show where FDG is by tracking the gamma rays given off by the radionuclide tagging the drug and producing three-dimensional images of their distribution within the body. PET/CT offers precise fusion of metabolic PET images with high-quality anatomical CT images.

For more information: www. snm.org


Related Content

News | Prostate Cancer

July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning ...

Time July 02, 2024
arrow
News | PET Imaging

June 18, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 18, 2024
arrow
News | PET Imaging

June 14, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 14, 2024
arrow
News | FDA

June 10, 2024 — Siemens Healthineers announces the Food and Drug Administration clearance of the Biograph Trinion, a ...

Time June 10, 2024
arrow
News | Radiology Business

May 14, 2024 — University Hospitals (UH) and Siemens Healthineers announce a 10-year strategic alliance that builds on ...

Time May 14, 2024
arrow
News | Cardiac Imaging

April 23, 2024 — CDL Nuclear Technologies, a pioneer in advanced diagnostic solutions, is proud to announce the launch ...

Time April 23, 2024
arrow
News | FDA

January 23, 2024 — Siemens Healthineers announces the Food and Drug Administration (FDA) clearance of syngo Virtual ...

Time January 23, 2024
arrow
News | Artificial Intelligence

January 23, 2024 — Quibim announced it has added an industry-leading cancer detection capability to its prostate tool ...

Time January 22, 2024
arrow
News | Radiology Business

December 27, 2023 — The American Roentgen Ray Society (ARRS) announced David M. Naeger, MD, as the 2024 ARRS ...

Time December 27, 2023
arrow
News | Radiopharmaceuticals and Tracers

December 6, 2023 — Philochem AG, a wholly owned subsidiary of Philogen S.p.A., and Blue Earth Diagnostics, a Bracco ...

Time December 06, 2023
arrow
Subscribe Now